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Abstract 
The endothelium mediates relaxations (dilatations) of the underlying vascular 
smooth muscle cells. The endothelium-dependent relaxations are due to the 
release of non-prostanoid vasodilator substances. The best characterized 
endothelium-derived relaxing factor (EDRF) is nitric oxide (NO). The 
endothelial cells also release substances (endothelium-derived 
hyperpolarizing factor, EDHF) that cause hyperpolarization of the cell 
membrane of the underlying vascular smooth muscle. The release of EDRF 
from the endothelium can be mediated by both pertussis toxin-sensitive Gi 
(alpha2-adrenergic activation, serotonin, thrombin) and insensitive Gq 
(adenosine diphosphate, bradykinin) coupling proteins. The ability of the 
endothelial cell to release relaxing factors can be upregulated by impregnation 
with estrogens, exercise and antioxidants, and down-regulated by oxidative 
stress and increased presence of oxidized LDL.  Following injury or apoptotic 
death, the endothelium regenerates. However, in regenerated endothelial cells, 
there is an early selective loss of the pertussis-toxin sensitive mechanisms of 
EDRF-release. Functional studies suggest that abnormal handling of LDL 
because of increased oxidative stress play a key role in this selective loss. 
Genomic analysis demonstrates the emergence of fatty acid binding protein-A 
(A-FBP) and metalloproteinase-7 (MMP7) in regenerated endothelial cells. 
The reduced release of NO resulting from the endothelial dysfunction in 
regenerated areas creates a locus minoris resistentiae which favors the 
occurrence of vasospasm and thrombosis as well as the initiation of 
atherosclerosis.  
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Introduction 
Thirty years ago Robert Furchgott demonstrated that the endothelial cell layer of the 
rabbit aorta mediates relaxation in response to acetylcholine (1). This ability of the 
endothelium to elicit relaxation of the underlying vascular smooth muscle has been 
extended to more relevant physiological stimuli [e.g. adenosine di (ADP)- and tri 
(ATP)-phosphate, thrombin, histamine, bradykinin, serotonin]. The endothelial cells 
cause relaxation by releasing one or more diffusible vasoactive substances 
[endothelium-derived relaxing factor (EDRF)]. The original EDRF described by 
Furchgott is nitric oxide (NO) (2-4). However, endothelial cells can affect the tone 
of the underlying smooth muscle in more than one way. Thus, besides NO, a 
number of endothelium-derived factors (EDHF) or the opening of myo-endothelial 
gap junctions can cause NO-independent hyperpolarizations of the   underlying 
vascular smooth muscle (5-7). In addition, endothelial cells can release 
endothelium-derived contracting factors, EDCF (2, 8, 9). Endothelial dysfunction 
occurs when the ability of the endothelial cells to release NO and EDHFs is reduced, 
that to produce EDCF is augmented. Such dysfunction appears to be an initial step 
in the chain of events that leads to atherosclerosis and coronary disease (10-13).  It 
has become a hallmark of cardiovascular disease and a predictor of cardiovascular 
events.  
Under normal conditions, native endothelial cells remain quiescent for many 
years, as long as they are in mutual physical contact [contact inhibition]. However, 
with ageing, endothelial turnover begins, and certain endothelial cells undergo 
apoptosis, detach and are washed away by the circulating blood, a process 
accelerated by the major cardiovascular risk factors. These cells are replaced 
rapidly by regenerated endothelial cells, whether produced by the proliferation of 
neighboring cells freed of the contact inhibition or originating from circulating 
endothelial progenitor cells. Whatever their origin, regenerated endothelial cells 
appear to be dysfunctional and this dysfunction favors the atherosclerotic process. 
This essay summarizes the evidence, mainly from the author’s laboratory(ies), 
which permits the preceding conclusion. 
The protective role of the native endothelium  
The release of NO plays a pivotal role in the protection exerted by the 
endothelium against coronary disease. Indeed, NO not only prevents abnormal 
constrictions (vasospasm), but also inhibits platelet aggregation as well as the 
expression of adhesion molecules at the surface of the endothelial cells, and hence 
prevents the adhesion and penetration of white blood cells (macrophages) (12, 13). 
The protective release of NO is triggered by the local generation of thrombin and 
products [5-hydroxytryptemine (serotonin, 5-HT) and adenosine diphosphate 
(ADP] platelets released by aggregating platelets [Figure 1].   
 
                                      Figure 1 
Of the substances released by aggregating platelets that trigger the release of 
NO, serotonin is the dominant one. The monoamine activates 5-HT1D serotonergic 
receptors on the endothelial cells which are coupled to endothelial nitric oxide 
synthase (eNOS) through pertussis toxin-sensitive Gi-proteins. ADP is a lesser 
contributor which stimulates endothelial P2y purinergic receptors, coupled to eNOS 
by Gq- proteins (12-14). If platelet aggregation is initiated in a coronary artery with 
a normal endothelium the release of serotonin and ADP and the subsequent 
activation of the coagulation cascade with the formation of thrombin combine to 
stimulate the endothelial cells to release more NO. NO diffuses to the underlying 
smooth muscle which relaxes, allowing the beginning aggregate to be flushed 
away by the flowing blood. It also, in synergy with endothelium-derived 
prostacyclin, exerts a feed-back inhibition of platelet aggregation. If the endothelial 
barrier is interrupted by injury, the aggregating platelets approach the vascular 
smooth muscle cells. They release thromboxane A2   and serotonin which cause an 
immediate vasoconstriction, underlying the vascular phase of hemostasis (12,13). 
The release of NO by the native endothelium in response to aggregating platelets is 
potentiated by dietary supplementation with ω3-unsaturated fatty acids (15,16) and 
impaired by hypercholesterolemia (17-19). 
Regenerated endothelial cells 
To study the impact of regeneration on endothelial function, a series of 
studies were conducted in the pig (18, 20-26). Under anaesthesia, a segment of the 
left anterior descending coronary artery [LAD] was gently denuded of the 
endothelium.  One month after this in vivo removal of the endothelium of part of 
the artery, a total relining of the endothelial surface had occurred. The regenerated 
endothelium expressed von Willebrand factor and contained eNOS. However, 
rings with such regenerated endothelium exhibited a major impairment of the 
endothelium-dependent relaxation to aggregating platelets, serotonin, ergonovin or 
thrombin, and a greater propensity to exhibit endothelium-dependent contractions. 
and the remaining relaxation was no longer inhibited by pertussis toxin. This 
indicated that Gi-protein coupling is defective in regenerated endothelial cells. By 
contrast, the Gq-coupling to eNOS appeared intact as relaxations to bradykinin 
were not impaired. Likewise, endothelium-dependent relaxations evoked by the 
calcium ionophore A23187 were comparable to those obtained in rings of the same 
arteries covered with native endothelial cells. Taken in conjunction with the 
normal response to bradykinin, this demonstrated that the intrinsic ability of the 
regenerated endothelium to produce NO was not affected. This series of 
experiments prompted the obvious conclusion that there is a selective loss of the 
Gi-dependent coupling to eNOS in regenerated endothelium [Figure 2]. This 
selective dysfunction was still obvious six months after the denudation procedure, 
indicating that in terms of the protective action of the endothelium, areas with 
regenerated endothelial cells constitute a permanent locus minoris resistentiae. The 
occurrence of this selective endothelial dysfunction could be prevented in part 
reduced by chronic intake of ω3-unsaturated fatty acid, and was exacerbated by 
hypercholesterolemia. Indeed, the combination of a hypercholesterolemic diet with 
the endothelium removal resulted in typical atherosclerotic lesions only in the 
previously denuded segments. Hence, we concluded that the dysfunction of 
regenerated endothelial cells is an initial step allowing the inflammatory reaction 
leading to the formation of atherosclerotic plaques (12, 13). Similar conclusions 
were reached concerning the endothelial dysfunction following heterotropic heart 
transplantation, a dysfunctions which was accentuated by injury of the coronary 
endothelium at implantation (27-29). 
   
                                          Figure 2             
To attempt to unravel the molecular mechanisms underlying the dysfunction 
of the regenerated endothelium primary cell cultures were grown derived from the 
endothelium harvested from segments of coronary arteries of the same hart covered 
with either native or regenerated endothelium (30-34). Compared to the former, 
those  derived from regenerated endothelium exhibited the following phenotypic 
changes: a]the presence of multiple enlarged cells and cells containing several 
nuclei, an appearance characteristic of early senescence, as confirmed by the 
greater presence of β-galactosidase; b] a reduced expression and activity of eNOS; 
c] a greater production of oxygen-derived free radicals (ROS); d] a greater uptake 
of  modified low-density lipoprotein cholesterol (LDL), a phenomenon confirmed 
in ex vivo measurements in intact coronary arteries lined with regenerated 
endothelium; e] a greater generation of oxidized LDL (oxLDL); f] a reduced 
activity of Gi-proteins despite the immunostaining demonstration of their 
unchanged presence, a phenomenon exacerbated by a hypercholesterolemic diet; 
and g] an indication of accelerated apoptosis. Increases in the extracellular 
concentration of oxLDL decrease the release of EDRF by endothelial cells and 
selectively inhibit endothelium-dependent relaxations evoked by serotonin. Thus it 
seems logical to conclude that the augmented presence of oxLDL in the 
regenerated endothelium initiates a selective dysfunction of the Gi-proteins and the 
resulting inability to respond to stimuli such as serotonin released from aggregating 
platelets, curtailing the protective role of the endothelial cells in preventing the 
atherosclerotic process. Obviously, this is but one of the negative impacts of 
oxLDL on endothelial function [Figure 3] (12, 13). 
 
                                   Figure 3 
A comparison was performed of the genomic profile of primary cultures of native 
and regenerated endothelial cells harvested from the same hearts, using a 
microarray approach (34). As could be anticipated, a large number of genes were 
expressed differentially in the two cell culture types. The down- or up-regulations 
of genes leading to the production of proteins involved in vasoconstriction, 
coagulation, apoptosis and inflammation were consistent with the phenotypic 
modifications mentioned above. Pathway analysis indicated the central role of 
ROS and oxyLDL in the observed changes in genomic expression. The most 
surprising finding was the emergence, only in cultures of regenerated endothelial 
cells of the genes for fatty acid binding protein A [A-FABP] and 
mineraloproteinase-7 [MMP7]. Whereas A-FABP is recognized as a player in the 
atherosclerotic process 35, 36), MMP7 so far has been mainly involved in 
inflammatory responses of the airways (37). Although many of the genomic 
changes observed in primary cultures of regenerated endothelial cells correspond 
to those obtained in cultures of native endothelium driven to senescence by 
multiple passaging, they were not identical. In particular, senescent native 
endothelial cells do not express A-FABP and MMP7, which makes them an 
inappropriate cell culture model for endothelial regeneration (38). 
Conclusions 
Native endothelial cells increase their release of NO in response to 
aggregating platelets (and thrombin). NO in turn relaxes the underlying vascular 
smooth muscle, inhibits platelet aggregation, and reduces the expression of 
adhesion molecules, and thus the adhesion and penetration of macrophages. It also 
inhibits the proliferation of vascular smooth muscle cells, prevents the production 
and action of endothelin-1 and exerts a negative feedback on the formation of ox 
LDL. Aging, injuries to the coronary endothelial layer, acceleration of endothelial 
turnover by risk factors [Western diet, pollution, smoking, diabetes, and 
hypertension] result in areas of the coronary arteries covered with regenerated 
endothelium. These regenerated cells differ from their native counterpart because 
of accelerated cell senescence, leading to a reduced production abnormal of NO. 
This then permits the inflammatory reaction leading to atherosclerosis (39, 40), in 
particular in patients with high cholesterol plasma levels.  
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Legends to Figures 
Figure 1 Postulated G-protein mediated signal transduction processes in a 
normal, native endothelial cell.  Activation of the cell causes the release of nitric 
oxide (NO), which has important protective effects in the vascular wall.  
Abbreviations: 5-HT, serotonin receptor; B, bradykinin receptor; P, purinoceptor; 
G, coupling proteins [From Ref. 13. By permission]. 
Figure 2 Effects of oxidized low-density lipoproteins (OXLDL) in a 
regenerated endothelial cell, resulting in the reduced release of nitric oxide (NO).  
Abbreviations: 5-HT, serotonin receptor; B, bradykinin receptor; P, purinoceptor; 
G, coupling proteins [From Ref. 13. By permission].   
Figure 3 Mechanisms of oxLDL-induced impairment of endothelial NO 
production.  The NO synthase (NOS) uses L-arginine to generate NO.  NO 
production could be attenuated in the presence of oxLDL by interfering with the 
supply of L-arginine to the enzyme through endogenous competitive inhibitors 
such as asymmetrical dimethyl-L-arginine (ADMA) as well as degradation of 
arginine through arginase.  NOS expression and specific activity are decreased by 
oxLDL through RhoA and PKC.  NO bioavailability is reduced by an oxLDL-
mediated activation of the NADPH oxidase, which leads to superoxide anion (O2-) 
formation.  This process facilitates the generation of peroxynitrite (ONOO-), which 
subsequently oxidizes tetrahydrobiopterin (BH4) of NOS, leading to NOS 
uncoupling.  Uncoupled NOS itself produces O2-, further promoting the process of 
BH4 oxidation.  Rho, member of the Rho protein family (either RhoA or Rac) 
[From Ref.13. By permission].   
 
 
 
 
 
